Analyst Reco. Exagen Inc.

Equities

XGN

US30068X1037

Market Closed - Nasdaq Other stock markets 21:30:01 26/04/2024 BST			5-day change	1st Jan Change
1.412 ^USD	+0.15%		+3.07%	-29.04%

04-26	Exagen Inc. Announces Changes in Board of Directors	CI
03-18	Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Adjusts Price Target on Exagen to $5 From $6, Maintains Buy Rating	22/03/23	MT
BTIG Adjusts Exagen's Price Target to $7 From $10, Keeps Buy Rating	17/11/22	MT
Canaccord Genuity Cuts Price Target on Exagen to $7 From $8, Affirms Buy Rating	15/11/22	MT
KeyBanc Downgrades Exagen to Sector Weight From Overweight, Citing 'Uncertain Test Pricing Process'	05/08/22	MT
KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating	13/05/22	MT
KeyBanc Adjusts Exagen's Price Target to $20 From $30, Reiterates Overweight Rating	25/03/22	MT
Cowen Adjusts Exagen's Price Target to $16 from $26, Reiterates Outperform Rating	23/03/22	MT
KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating	11/11/21	MT
EXAGEN : BTIG Adjusts Exagen's Price Target to $20 From $23, Reiterates Buy Rating	10/08/21	MT
EXAGEN : Canaccord Genuity Initiates Exagen at Buy Rating With $25 Price Target	15/04/21	MT
EXAGEN : KeyBanc Initiates Exagen at Overweight with $32 Price Target	10/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer